Executed in August 2008, the agreement allows Roche to develop hepatitis C viral (HCV) compounds while using Metabasis’ liver-targeting technology.
Earlier, in April Roche has paid $6.5m payment to Ligand Pharma following Roche’s initiation of RG7348 Phase I clinical trial.
As per the collaboration and licensing agreement Roche’s termination is expected to be in effect after 60 days prior written notice.
Following the termination of the deal, Roche will not be able to get into any development and commercialisation agreement on the related compounds.